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Abstract
Background Tumor recurrence after resection of hepato-
cellular carcinoma is a common phenomenon. Re-resection
and radiofrequency ablation (RFA) are good options for
treating recurrent HCC. This study compared the efﬁcacy
of these two modalities in the treatment of intrahepatic
HCC recurrence after hepatectomy.
Methods From January 2001 to December 2008, a total of
179 patients developed intrahepatic HCC recurrence after
hepatectomy. To treat the recurrence, 29 patients under-
went re-resection and 45 patients had RFA. Patient char-
acteristics, clinicopathologic data, and survival outcomes
were reviewed.
Results Child-Pugh status, time to develop ﬁrst recur-
rence (12.2 vs. 8.7 months), and recurrent tumor size (2.1
vs. 2.1 cm) were comparable for the two groups. Time to
develop a second intrahepatic recurrence after re-resection
and RFA was 5.9 and 4.0 months respectively. The 1-, 3-,
and 5-year disease-free survival rates were 41.4%, 24.2%,
and 24.2% after re-resection and 32.2%, 12.4%, and 9.3%
after RFA (p = 0.14). The 1-, 3-, and 5-year overall sur-
vival rates were 89.7%, 56.5%, and 35.2% after re-resec-
tion and 83.7%, 43.1%, and 29.1% after RFA (p = 0.48).
For the second recurrence, 33.3% of patients underwent a
second round of RFA and 10.0% underwent a third
resection.
Conclusions The two treatment modalities attained sim-
ilar survival beneﬁts in the management of recurrent HCC
after hepatectomy. The high repeatability of RFA and that
it can be delivered percutaneously render it a preferred
treatment option for selected patients.
Introduction
Hepaticresectionremainsanimportantcurativetreatmentfor
hepatocellular carcinoma (HCC). Nonetheless, postresection
tumor recurrence is common with a 5-year recurrence rate
of[50% [1, 2]. The treatment algorithm for recurrent HCC
varies from center to center, and there is not yet a consensus
on the most appropriate treatment for postresection tumor
recurrence. Nonsurgical treatment such as transarterial oily
chemoembolization is, at best, a palliative treatment after
which long-term survival is seldom observed [3, 4]. Salvage
transplantation probably produces the best survival results as
it removes both the tumor and the cirrhotic liver [5, 6].
However,ashortageoflivergrafts,stringentpatientselection
criteria,andanormalliverbiochemicalproﬁlethatconstitutes
a low Model for End-stageLiver Disease score often relegate
patients with recurrent HCC to the least priority to receive a
graft before the disease progresses. Re-resection would be
an ideal alternative, which was shown to be an effective
approach to prolong survival [7], but its feasibility is limited
by the small liver remnant and inadequate liver function
reserve. Another treatment option is radiofrequency ablation
(RFA), which that is applicable even to patients with bor-
derline liver function and can be delivered via the percuta-
neousaswellastheopenapproach.Theaimofthisstudywas
to determine if RFA or re-resection is the preferred treatment
modality for the management of intrahepatic recurrence after
hepatectomy for HCC.
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From January 2001 to December 2008, 669 patients
underwent hepatic resection for HCC at the Department of
Surgery in Queen Mary Hospital, The University of Hong
Kong. At the time of the data analysis, 257 patients
remained free of recurrence, 179 patients had developed
intrahepatic recurrence, 115 patients haddeveloped extra-
hepatic recurrence, and 118 patients had developed both.
Among the 179 patients with intrahepatic recurrence, 74
patients underwent either re-resection or RFA as the sec-
ondary treatment, and they formed the focus of interest in
this study. Prospectively collected data on patient charac-
teristics, clinicopathologic features, and survival outcomes
were reviewed.
Diagnostic criteria for recurrent HCC
The follow-up protocol for patients after hepatectomy for
primary HCC in our center consisted of computed
tomography (CT) or magnetic resonance imaging (MRI) of
the liver 1 month after hepatic resection to conﬁrm mac-
roscopic tumor clearance. Thereafter, surveillance for
tumor recurrence was conducted using CT or MRI scans of
the liver every 3 months with serial measurements of
serum a-fetoprotein (AFP) and liver biochemistry. Intra-
hepatic recurrence is deﬁned as a new lesion with arterial
enhancement and portal venous washout on contrast-
enhanced CT or MRI scans with or without an elevated
serum AFP level ([200 ng/ml).
Selection criteria for re-resection or RFA
as a secondary treatment
Only patients with Child-Pugh class A cirrhosis and
selected patients with Child-Pugh class B cirrhosis were
considered for re-resection or RFA. The usual indication
for re-resection was a solitary or oligonodular tumor irre-
spective of tumor size within a monosegment of liver in the
presence of a sufﬁcient future liver remnant. It was gen-
erally avoided in the presence of (1) gross ascites, and/or
(2) an indocyanine green retention rate of[15% at 15 min,
and/or (3) a platelet count\100 9 10
9/L, signifying severe
portal hypertension. RFA was selected when the recurrent
tumor was (1) \6 cm or there were three or fewer tumor
nodules, and/or (2) in a deep-seated intraparenchymal
location where anatomic re-resection would remove more
than one segment of liver, leading to insufﬁcient remnant
liver volume. Needle biopsy for histologic conﬁrmation
was performed before application of RFA, and the tract
was subsequently ablated on withdrawal of the RFA probe.
The percutaneous approach was usually considered ﬁrst
(n = 22) unless the tumor was situated near the gallbladder
or the bowel loops or when there was difﬁculty localizing
the tumor with transabdominal ultrasonography. The open
or laparoscopic approach was selected otherwise (n = 23).
Statistical analysis
Continuous variables were expressed in medians (inter-
quartile range) and compared using the Mann–Whitney
U-test. Categoric variables were compared with the v
2 test
or Fisher’s exact test when appropriate. Overall survival
and disease-free survival of the two study groups were
estimated by the Kaplan-Meier method. Comparison of
survival between groups was performed with the log-rank
test. Disease-free survival after treatment of intrahepatic
recurrence was deﬁned as the period from the date of
treatment of recurrent HCC to the date of the second tumor
recurrence or death. Overall survival after hepatectomy
was deﬁned as the period from the date of hepatectomy for
the primary HCC to the date of death related to any cause.
Overall survival after treatment of intrahepatic recurrence
was deﬁned as the period from the date of treatment for the
ﬁrst recurrence to the date of death related to any cause. A
p value B0.05 was considered to be signiﬁcant. Statistical
analysis was performed using the SPSS 16.0 computer
software program.
Results
The median follow-up duration was 44.9 months
(8.3–112.0 months). Table 1 shows the patients’ charac-
teristics and liver function proﬁles at the time of the
intrahepatic recurrence. Patients in the RFA group were
older than those in the re-resection group. The two groups
had a similar incidence of co-morbid illness and similar
viral hepatitis carrier rates. All patients in the re-resection
group had Child-Pugh class A cirrhosis, whereas 88.9% of
patients in the RFA group were of Child-Pugh class A and
11.1% were of Child-Pugh class B (p = 0.17). Pretreat-
ment liver biochemistry and renal function at the time of
recurrence were comparable for the two groups except that
patients in the RFA group had a higher serum bilirubin
level and a lower serum albumin level. With regard to the
pathology of the primary HCC (Table 2), the two groups
shared similar features in terms of tumor nodularity, degree
of tumor cell differentiation, and distribution of tumor
staging [American Joint Committee on Cancer (AJCC) 6th
edition). The RFA group, however, had a larger primary
tumor size than the re-resection group (5.5 vs. 3.5 cm,
p = 0.01), suggesting that tumors in the former group
might be more aggressive. Time to develop ﬁrst recurrence
was longer in the re-resection group, although the differ-
ence was not statistically signiﬁcant (12.2 vs. 8.7 months,
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123p = 0.84). Pathological characteristics of recurrent tumors
(Table 3) were similar in the two groups in terms of tumor
size (p = 0.73), tumor nodularity (p = 0.48), and serum
AFP level (p = 0.85). Table 4 showed the postoperative
outcomes of patients undergoing re-resection and RFA via
the open or laparoscopic approach (n = 23). Seven patients
developed a total of 11 procedure-related morbidities in the
re-resection group, with most of them Dindo-Clavien grade
II. One patient in the RFA group developed aggressive
lymphoproliferative disease after open RFA and suc-
cumbed during the same hospital admission. The inci-
dences of procedure-related morbidity (p = 0.27) and
hospital mortality (p = 0.91) were not statistically differ-
ent for the two groups.
Table 5 illustrates the patterns of the second recurrence
in the two groups after treatment of the ﬁrst intrahepatic
recurrence and the subsequent management. At the time of
analysis, 27.6% of the patients in the re-resection group
and 15.6% of the patients in the RFA group remained free
of recurrence. The time to develop a second recurrence was
5.9 months in the re-resection group and 4.0 months in the
RFA group (p = 0.30). By excluding tumors with a posi-
tive re-resection margin (n = 3, 10.3%) and tumors that
were incompletely ablated (n = 14, 31.1%) during
Table 1 Patient characteristics and liver function proﬁle at the time
of recurrence after hepatectomy
Characteristic Re-resection
(n = 29)
RFA
(n = 45)
p
Age (years) 52 (38–79) 59 (36–80) 0.03
Co-morbid illness 11 (37.9%) 23 (51.1%) 0.27
Carrier of hepatitis B virus 26 (89.7%) 40 (88.9%) 1.00
Carrier of hepatitis C virus 1 (3.6%) 3 (7.1%) 0.39
Child-Pugh class A 29 (100%) 40 (88.9%) 0.17
Child-Pugh class B 0 5 (11.1%)
Serum bilirubin (lmol/L) 11 (6–35) 14 (5–61) 0.02
Serum alanine
transaminase (l/L)
51 (17–99) 47.5 (12–379) 0.83
Serum aspartate
transaminase (l/L)
48 (19–77) 43 (20–177) 0.76
Serum albumin (g/dl) 41 (28–48) 39 (25–49) 0.03
Platelet count (910
9/L) 136 (79–270) 142 (46–291) 0.83
Serum urea (mmol/L) 4.9 (2.6–10.5) 5.4 (2.6–20.6) 0.23
Serum creatinine (lmol/L) 82 (44–137) 89 (49–185) 0.23
Nontumorous liver parenchyma
Normal 4 (13.8%) 5 (11.1%) 0.17
Chronic hepatitis/
cirrhosis
25 (86.2%) 40 (88.9%)
RFA radiofrequency ablation
Table 2 Pathologic features of primary HCC
Feature Re-resection
(n = 29)
RFA (n = 45) p
Primary tumor size (cm) 3.5 (1.0–14.5) 5.5 (1.5–22.0) 0.01
No. of tumor nodules 1 (1–3) 1 (1–multiple) 0.11
Tumor cell
differentiation
a
0.86
Well differentiation 4 (13.8%) 8 (17.8%)
Moderate
differentiation
21 (72.4%) 29 (64.4%)
Poor differentiation 4 (13.8%) 6 (13.3%)
Serum a-fetoprotein
(ng/ml)
64 (2–167,138) 90 (1–197,122) 0.85
AJCC stage 0.12
I 12 (41.4%) 18 (40.0%)
II 15 (51.7%) 19 (42.2%)
III 2 (6.9%) 8 (17.8%)
HCC hepatocellular carcinoma, AJCC American Joint Committee on
Cancer
a Two patients in the RFA group had a sampling error in the tumor
biopsy specimen
Table 3 Tumor characteristics of intrahepatic HCC recurrence
Characteristic Re-resection
(n = 29)
RFA
(n = 45)
p
Time to recurrence
(months)
12.2 (1.8–84.3) 8.7 (1.0–88.5) 0.84
Tumor size (cm) 2.1 (0.8–5.5) 2.2 (0.8–6.0) 0.73
Solitary tumor
recurrence
21 (72.4%) 29 (64.4%) 0.48
Serum a-fetoprotein
(ng/ml)
64 (2–167,138) 90 (1–197,122) 0.85
Table 4 Postoperative outcomes after treatment of recurrent HCC
Outcome Re-resection
(n = 29)
Open RFA
(n = 23)
p
Postoperative morbidities (no.) 7 (24.1%) 2 (8.7%) 0.27
Pleural effusion 5 1 0.33
Pneumonia 1 1 1.00
Wound infection 3 0 0.32
Intraabdominal hemorrhage 1 0 1.0
Septicemia 1 0 1.0
Hospital mortality (no.) 0 1 0.91
Dindo-Clavien classiﬁcation [20]
II 8 2
IIIa 1 0
IIIb 1 0
IVa 1 0
V0 1
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123treatment for the ﬁrst recurrence, the times to develop a
second recurrence in the re-resection group and the RFA
group was extended to 6.3 months and 9.5 months,
respectively (p = 0.25). The 1-, 3-, and 5-year overall
survival rates from the time of hepatectomy for primary
HCC in the re-resection group were 89.7%, 82.3%, and
55.7%, respectively. The RFA group had corresponding
rates of 95.6%, 68.2%, and 44.5% (Fig. 1). The 1-, 3-, and
5-year overall survival rates after treatment of the ﬁrst
intrahepatic recurrence in the re-resection group were
89.7%, 56.5%, and 35.2%, respectively. The RFA group
had corresponding rates of 83.7%, 43.1%, and 29.1%
(Fig. 2). The 1-, 3-, and 5-year disease-free survival rates
after treatment of the ﬁrst intrahepatic recurrence in the
re-resection group were 41.4%, 24.2%, and 24.2%,
respectively. The corresponding rates in the RFA group
were 32.2%, 12.4%, and 9.3% (Fig. 3).
Univariate analysis of nine clinical parameters (Table 6)
showed that time to the ﬁrst intrahepatic recurrence after
hepatectomy, time to the second recurrence after treatment
of the ﬁrst intrahepatic recurrence, and recurrence in more
than one organ after treatment of the ﬁrst intrahepatic
recurrence were signiﬁcant clinical factors that adversely
affected overall survival after hepatectomy for primary
HCC. In the multivariate analysis, only recurrence in more
than one organ after treatment of the ﬁrst intrahepatic
recurrence remained an independent unfavorable prognos-
tic factor for overall survival (p\0.001, hazard ratio
4.424, conﬁdence interval 2.313–8.462).
Discussion
With the reﬁnement in preoperative liver function assess-
ment [8] and surgical techniques for hepatectomy over the
past decade leading to decreased postoperative morbidity
and mortality [9, 10], more patients with cirrhotic livers are
now amenable to major hepatectomy. Nonetheless, pos-
tresection tumor recurrence is common, with a 5-year
recurrence rate [50% [1, 2, 11, 12]. In all, 80% of the
Table 5 Recurrence pattern and subsequent management after
treatment of intrahepatic recurrence
Recurrence Re-resection
(n = 29)
RFA
(n = 45)
p
Recurrence pattern 0.23
No recurrence 8 (27.6%) 7 (15.6%)
Intrahepatic only 13 (44.8%) 19 (42.2%)
Extrahepatic only 2 (6.9%) 1 (2.2%)
Intrahepatic and extrahepatic 6 (20.7%) 18 (40.0%)
Treatment of second
intrahepatic recurrence
0.66
Alcohol injection 1 (7.7%) 0 (0%)
Transarterial oily
chemoembolization
5 (38.5%) 4 (21.1%)
Re-resection 1 (7.7%) 3 (15.8%)
Liver transplantation 0 1 (5.3%)
Systemic chemotherapy 0 1 (5.3%)
RFA 3 (23.1%) 5 (26.3%)
Conservative 3 (23.1%) 5 (26.3%) Fig. 1 Overall survival after hepatectomy for primary hepatocellular
carcinoma. RFA radiofrequency ablation
Fig. 2 Overall survival after treatment of intrahepatic recurrence
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123recurrences develop within the liver remnant [13], so it is
important for surgeons to select the most appropriate
treatment for patients with recurrent HCC. Cirrhosis is a
known risk factor for intrahepatic recurrence [1, 13].
Treatment of intrahepatic recurrence poses several
technical challenges, including a small liver remnant,
inadequate liver function reserve, signiﬁcant adhesion from
a previous operation, and proximity of the tumor to major
vascular or biliary structures. All of these conditions are
relative contraindications to re-resection. The Kyoto group
demonstrated a signiﬁcant improvement in overall survival
after active treatment of intrahepatic recurrence by either
re-hepatectomy or RFA [14]. However, their study did not
explore the most appropriate choice of surgical treatment
for intrahepatic recurrence.
Our study showed that RFA could achieve long-term
survival outcomes similar to those seen with re-resection in
patients with recurrent HCC. After excluding confounding
factors (positive resection margin, incomplete ablation) for
further intrahepatic recurrence, the survival beneﬁt of RFA
remained unchanged. There are several reasons why RFA
should be the preferred treatment option for intrahepatic
recurrence. First, RFA can be delivered percutaneously,
thereby avoiding a second operation. Second, RFA is
applicable even to tumors proximal to major intrahepatic
bile ducts. The practice of bile duct cooling (i.e., instilla-
tion of cold normal saline into the common bile duct via
the cystic duct stump [15] or nasobiliary drain [16, 17]) can
protect the bile duct from damage by the heat-sink effect of
RFA. In our experience, about 3.5% of the patients
undergoing RFA required bile duct cooling, and no biliary
complications were observed in these patients [15]. Third,
conservation of nontumorous liver parenchyma and negli-
gible blood loss associated with RFA minimize the degree
of surgical insult to the small and cirrhotic liver remnant.
Fourth, repeatability is a major advantage of RFA. Our
study showed that 26.3% of patients in the RFA group and
23.1% of patients in the re-resection group underwent RFA
for their second intrahepatic recurrence, whereas less than a
ﬁfth of the patients in the RFA group and re-resection
group were amenable to repeated resection for second
intrahepatic recurrence. These four factors contribute to the
safety and feasibility of RFA in the management of intra-
hepatic recurrence after hepatectomy.
Despite the fact that the chance of survival was
improved by further surgical treatment, early ﬁrst intrahe-
patic recurrence after hepatectomy, early second intrahe-
patic recurrence after either RFA or re-resection, and
second recurrence in more than one organ remained poor
Fig. 3 Disease-free survival after treatment of intrahepatic
recurrence
Table 6 Univariate analysis identifying prognostic factors for overall
survival after hepatectomy
Clinical parameter Median survival
(months)
p
Age (years) 0.18
B55 (n = 38) 51.20
[55 (n = 36) 76.70
Tumor size (cm) 0.26
B5.0 (n = 46) 66.97
[5.0 (n = 28) 59.22
Viral hepatitis positivity 0.56
Hepatitis B (n = 66) 55.24
Hepatitis C (n = 4) 76.70
Child-Pugh classiﬁcation 0.78
A( n = 70) 59.97
B( n = 4) 16.92
Re-resection 0.19
Yes (n = 33) 88.70
No (n = 41) 46.07
Time to ﬁrst intrahepatic
recurrence
\0.001
B12 months (n = 38) 6.67
[12 months (n = 36) 36.12
Time to second tumor recurrence \0.001
B12 months (n = 21) 5.29
[12 months (n = 19) 30.23
Single-site recurrence
a \0.001
Yes (n = 48) [112.03
No (n = 26) 36.64
Intrahepatic recurrence 0.29
Solitary (n = 50) 61.2
Multiple (n = 24) 46.1
a Denotes recurrence in one organ after treatment of a ﬁrst intrahe-
patic recurrence
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123prognostic factors for overall survival in patients with
recurrent HCC after hepatectomy. Further research should
therefore focus on adjuvant treatment after resection of a
primary HCC. In fact, our recent study demonstrated the
survival beneﬁt of postresection antiviral therapy in anti-
viral-naive patients with early staged tumors [18]. Alter-
natively, results from the STORM trial [19] might identify
a new avenue in the area of adjuvant treatment for HCC in
the future.
Our study design was not without pitfalls: a small
sample size, nonrandomization regarding choices of treat-
ment, and selection bias. However, a randomized con-
trolled trial might not be practical as fewer than 50% of the
patients with a ﬁrst intrahepatic recurrence were eligible
for further surgical treatment in this study.
Conclusions
Radiofrequency ablation achieved long-term survival out-
come similar to those seen with re-resection in the treat-
ment of intrahepatic recurrence after hepatectomy.
Secondary treatment of recurrent HCC after hepatectomy
remains a challenging issue for hepatobiliary surgeons.
However, a persevering attitude is mandatory in the long-
term management of HCC to improve the chance of
treatment for recurrent disease. The fact that RFA can be
delivered percutaneously and its high repeatability render it
a preferred treatment option in selected patients with HCC
recurrence.
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